WEST HARRISON, N.Y.--(BUSINESS WIRE)--Generex Biotechnology Corporation’s (NASDAQ:GNBT) race to pioneer drug delivery of oral insulin through the inner lining of the mouth was recently featured in an article that appeared in the April 2, 2008 second issue of Flaherty Special Situations Newsletter published by Flaherty Financial News Inc. The piece reported on the company’s first commercial order in India and a $20.7 million capital raise. Subsequently, Generex announced North American initiation of its Generex Oral-lyn™ Phase III Diabetes study to compare efficacy with that of standard regular injected insulin therapy. Unlike inhaled insulin products, buccally-absorbed Generex Oral-lyn does not enter the lungs and leave harmful deposits there as inhaled products do.
